Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sertraline combined with radiotherapy and temozolomide in newly diagnosed glioblastoma multiforme
ChiCTR2600123447Phase 3Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sertraline in glioblastoma (GBM) (2 arms), sponsored by Tangdu Hospital. Primary endpoints: Progression-free survival, PFS rate at 6 months and 5 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
sertraline
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2600123447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123447.